

- [0024] (ii) a light chain variable (VL) region incorporating the following CDRs:
- [0025] LC-CDR1 having the amino acid sequence of SEQ ID NO:41
- [0026] LC-CDR2 having the amino acid sequence of SEQ ID NO:308
- [0027] LC-CDR3 having the amino acid sequence of SEQ ID NO:43.
- [0028] In some embodiments the antigen-binding molecule comprises:
- [0029] (i) a heavy chain variable (VH) region incorporating the following CDRs:
- [0030] HC-CDR1 having the amino acid sequence of SEQ ID NO:244
- [0031] HC-CDR2 having the amino acid sequence of SEQ ID NO:34
- [0032] HC-CDR3 having the amino acid sequence of SEQ ID NO:35; and
- [0033] (ii) a light chain variable (VL) region incorporating the following CDRs:
- [0034] LC-CDR1 having the amino acid sequence of SEQ ID NO:41
- [0035] LC-CDR2 having the amino acid sequence of SEQ ID NO:245
- [0036] LC-CDR3 having the amino acid sequence of SEQ ID NO:43.
- [0037] In some embodiments the antigen-binding molecule comprises:
- [0038] (i) a heavy chain variable (VH) region incorporating the following CDRs:
- [0039] HC-CDR1 having the amino acid sequence of SEQ ID NO:290
- [0040] HC-CDR2 having the amino acid sequence of SEQ ID NO:291
- [0041] HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and
- [0042] (ii) a light chain variable (VL) region incorporating the following CDRs:
- [0043] LC-CDR1 having the amino acid sequence of SEQ ID NO:41
- [0044] LC-CDR2 having the amino acid sequence of SEQ ID NO:309
- [0045] LC-CDR3 having the amino acid sequence of SEQ ID NO:43.
- [0046] In some embodiments the antigen-binding molecule comprises:
- [0047] (i) a heavy chain variable (VH) region incorporating the following CDRs:
- [0048] HC-CDR1 having the amino acid sequence of SEQ ID NO:290
- [0049] HC-CDR2 having the amino acid sequence of SEQ ID NO:291
- [0050] HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and
- [0051] (ii) a light chain variable (VL) region incorporating the following CDRs:
- [0052] LC-CDR1 having the amino acid sequence of SEQ ID NO:41
- [0053] LC-CDR2 having the amino acid sequence of SEQ ID NO:295 or SEQ ID NO:300
- [0054] LC-CDR3 having the amino acid sequence of SEQ ID NO:43.
- [0055] In some embodiments the antigen-binding molecule comprises:
- [0056] (i) a heavy chain variable (VH) region incorporating the following CDRs:
- [0057] HC-CDR1 having the amino acid sequence of SEQ ID NO:290
- [0058] HC-CDR2 having the amino acid sequence of SEQ ID NO:291
- [0059] HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and
- [0060] (ii) a light chain variable (VL) region incorporating the following CDRs:
- [0061] LC-CDR1 having the amino acid sequence of SEQ ID NO:41
- [0062] LC-CDR2 having the amino acid sequence of SEQ ID NO:295
- [0063] LC-CDR3 having the amino acid sequence of SEQ ID NO:43.
- [0064] In some embodiments the antigen-binding molecule comprises:
- [0065] (i) a heavy chain variable (VH) region incorporating the following CDRs:
- [0066] HC-CDR1 having the amino acid sequence of SEQ ID NO:290
- [0067] HC-CDR2 having the amino acid sequence of SEQ ID NO:291
- [0068] HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and
- [0069] (ii) a light chain variable (VL) region incorporating the following CDRs:
- [0070] LC-CDR1 having the amino acid sequence of SEQ ID NO:41
- [0071] LC-CDR2 having the amino acid sequence of SEQ ID NO:300
- [0072] LC-CDR3 having the amino acid sequence of SEQ ID NO:43.
- [0073] In some embodiments the antigen-binding molecule comprises:
- [0074] (i) a heavy chain variable (VH) region incorporating the following CDRs:
- [0075] HC-CDR1 having the amino acid sequence of SEQ ID NO:33
- [0076] HC-CDR2 having the amino acid sequence of SEQ ID NO:277
- [0077] HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and
- [0078] (ii) a light chain variable (VL) region incorporating the following CDRs:
- [0079] LC-CDR1 having the amino acid sequence of SEQ ID NO:41
- [0080] LC-CDR2 having the amino acid sequence of SEQ ID NO:42
- [0081] LC-CDR3 having the amino acid sequence of SEQ ID NO:43.
- [0082] In some embodiments the antigen-binding molecule comprises:
- [0083] (i) a heavy chain variable (VH) region incorporating the following CDRs:
- [0084] HC-CDR1 having the amino acid sequence of SEQ ID NO:33
- [0085] HC-CDR2 having the amino acid sequence of SEQ ID NO:286
- [0086] HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and